Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging

Y. Ni, Cristina D Pislaru, H. Bosmans, S. Pislaru, Y. Miao, J. Bogaert, S. Dymarkowski, J. Yu, W. Semmler, F. Van de Werf, A. L. Baert, G. Marchal

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The aim of this study was to compare intracoronary (i.c.) administration of Gadophrin-2, a necrosis-avid contrast agent (NACA), and nonspecific agent Gd-DTPA for determination of myocardial viability (MV) in acute myocardial infarction (AMI) with MRI. Reperfused AMI was induced in 12 dogs by transcatheter balloon occlusion of coronary artery. In 6 dogs each, Gd-DTPA at 0.1 mmol/kg or Gadophrin-2 at 0.005 mmol/kg was administered into coronary artery by fast bolus (n = 3) or slow infusion (n = 3). Serial ECG-triggered cardiac MRI of T1-weighted segmented turbo fast low-angle shot (FLASH) sequence was conducted and compared with triphenyltetrazolium chloride (TTC) histochemical staining. The contrast ratio and infarct size were quantified and analysed statistically. No cardiovascular side effects were found with local delivery of both agents. After i.c. administration, Gadophrin-2 induced a strong (CR ≥ 1.78) and persistent (≥ 10 h) contrast enhancement of infarcted region. The infarct size defined with Gadophrin-2 was almost identical to that with TTC staining throughout the postcontrast period. With a dose 20 times higher, Gd-DTPA also strongly enhanced infarct-to-normal contrast; however, the enhancement diminished with time, i.e. from early strong to later faint enhancement and eventual loss of contrast. The delineated infarct size was also unstable, i.e. from early overestimation to later underestimation and eventual disappearance of the enhanced infarct. In combination with PTCA procedure, i.c. administration of MRI contrast agents may prove useful for post-procedure verification of diagnosis. The NACA-enhanced MRI may serve as an in vivo surrogate of postmortem histochemical staining for determination of MV. Although applicable in clinical setting, cardiac MRI with nonspecific Gd-DTPA is less reliable and should be performed within less than 1 h after contrast.

Original languageEnglish (US)
Pages (from-to)876-883
Number of pages8
JournalEuropean Radiology
Volume11
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Gadolinium DTPA
Contrast Media
Staining and Labeling
Coronary Vessels
Necrosis
Myocardial Infarction
Dogs
Balloon Occlusion
Electrocardiography
gadophrin-2
triphenyltetrazolium

Keywords

  • Acute myocardial infarction
  • Intracoronary injection
  • Metalloporphyrins
  • MRI
  • Myocardial viability
  • Necrosis-avid contrast agents

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging. / Ni, Y.; Pislaru, Cristina D; Bosmans, H.; Pislaru, S.; Miao, Y.; Bogaert, J.; Dymarkowski, S.; Yu, J.; Semmler, W.; Van de Werf, F.; Baert, A. L.; Marchal, G.

In: European Radiology, Vol. 11, No. 5, 2001, p. 876-883.

Research output: Contribution to journalArticle

Ni, Y, Pislaru, CD, Bosmans, H, Pislaru, S, Miao, Y, Bogaert, J, Dymarkowski, S, Yu, J, Semmler, W, Van de Werf, F, Baert, AL & Marchal, G 2001, 'Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging', European Radiology, vol. 11, no. 5, pp. 876-883. https://doi.org/10.1007/s003300000791
Ni, Y. ; Pislaru, Cristina D ; Bosmans, H. ; Pislaru, S. ; Miao, Y. ; Bogaert, J. ; Dymarkowski, S. ; Yu, J. ; Semmler, W. ; Van de Werf, F. ; Baert, A. L. ; Marchal, G. / Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging. In: European Radiology. 2001 ; Vol. 11, No. 5. pp. 876-883.
@article{c28fdfe589374723bd1a8b9e15e8ba6b,
title = "Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging",
abstract = "The aim of this study was to compare intracoronary (i.c.) administration of Gadophrin-2, a necrosis-avid contrast agent (NACA), and nonspecific agent Gd-DTPA for determination of myocardial viability (MV) in acute myocardial infarction (AMI) with MRI. Reperfused AMI was induced in 12 dogs by transcatheter balloon occlusion of coronary artery. In 6 dogs each, Gd-DTPA at 0.1 mmol/kg or Gadophrin-2 at 0.005 mmol/kg was administered into coronary artery by fast bolus (n = 3) or slow infusion (n = 3). Serial ECG-triggered cardiac MRI of T1-weighted segmented turbo fast low-angle shot (FLASH) sequence was conducted and compared with triphenyltetrazolium chloride (TTC) histochemical staining. The contrast ratio and infarct size were quantified and analysed statistically. No cardiovascular side effects were found with local delivery of both agents. After i.c. administration, Gadophrin-2 induced a strong (CR ≥ 1.78) and persistent (≥ 10 h) contrast enhancement of infarcted region. The infarct size defined with Gadophrin-2 was almost identical to that with TTC staining throughout the postcontrast period. With a dose 20 times higher, Gd-DTPA also strongly enhanced infarct-to-normal contrast; however, the enhancement diminished with time, i.e. from early strong to later faint enhancement and eventual loss of contrast. The delineated infarct size was also unstable, i.e. from early overestimation to later underestimation and eventual disappearance of the enhanced infarct. In combination with PTCA procedure, i.c. administration of MRI contrast agents may prove useful for post-procedure verification of diagnosis. The NACA-enhanced MRI may serve as an in vivo surrogate of postmortem histochemical staining for determination of MV. Although applicable in clinical setting, cardiac MRI with nonspecific Gd-DTPA is less reliable and should be performed within less than 1 h after contrast.",
keywords = "Acute myocardial infarction, Intracoronary injection, Metalloporphyrins, MRI, Myocardial viability, Necrosis-avid contrast agents",
author = "Y. Ni and Pislaru, {Cristina D} and H. Bosmans and S. Pislaru and Y. Miao and J. Bogaert and S. Dymarkowski and J. Yu and W. Semmler and {Van de Werf}, F. and Baert, {A. L.} and G. Marchal",
year = "2001",
doi = "10.1007/s003300000791",
language = "English (US)",
volume = "11",
pages = "876--883",
journal = "European Radiology",
issn = "0938-7994",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging

AU - Ni, Y.

AU - Pislaru, Cristina D

AU - Bosmans, H.

AU - Pislaru, S.

AU - Miao, Y.

AU - Bogaert, J.

AU - Dymarkowski, S.

AU - Yu, J.

AU - Semmler, W.

AU - Van de Werf, F.

AU - Baert, A. L.

AU - Marchal, G.

PY - 2001

Y1 - 2001

N2 - The aim of this study was to compare intracoronary (i.c.) administration of Gadophrin-2, a necrosis-avid contrast agent (NACA), and nonspecific agent Gd-DTPA for determination of myocardial viability (MV) in acute myocardial infarction (AMI) with MRI. Reperfused AMI was induced in 12 dogs by transcatheter balloon occlusion of coronary artery. In 6 dogs each, Gd-DTPA at 0.1 mmol/kg or Gadophrin-2 at 0.005 mmol/kg was administered into coronary artery by fast bolus (n = 3) or slow infusion (n = 3). Serial ECG-triggered cardiac MRI of T1-weighted segmented turbo fast low-angle shot (FLASH) sequence was conducted and compared with triphenyltetrazolium chloride (TTC) histochemical staining. The contrast ratio and infarct size were quantified and analysed statistically. No cardiovascular side effects were found with local delivery of both agents. After i.c. administration, Gadophrin-2 induced a strong (CR ≥ 1.78) and persistent (≥ 10 h) contrast enhancement of infarcted region. The infarct size defined with Gadophrin-2 was almost identical to that with TTC staining throughout the postcontrast period. With a dose 20 times higher, Gd-DTPA also strongly enhanced infarct-to-normal contrast; however, the enhancement diminished with time, i.e. from early strong to later faint enhancement and eventual loss of contrast. The delineated infarct size was also unstable, i.e. from early overestimation to later underestimation and eventual disappearance of the enhanced infarct. In combination with PTCA procedure, i.c. administration of MRI contrast agents may prove useful for post-procedure verification of diagnosis. The NACA-enhanced MRI may serve as an in vivo surrogate of postmortem histochemical staining for determination of MV. Although applicable in clinical setting, cardiac MRI with nonspecific Gd-DTPA is less reliable and should be performed within less than 1 h after contrast.

AB - The aim of this study was to compare intracoronary (i.c.) administration of Gadophrin-2, a necrosis-avid contrast agent (NACA), and nonspecific agent Gd-DTPA for determination of myocardial viability (MV) in acute myocardial infarction (AMI) with MRI. Reperfused AMI was induced in 12 dogs by transcatheter balloon occlusion of coronary artery. In 6 dogs each, Gd-DTPA at 0.1 mmol/kg or Gadophrin-2 at 0.005 mmol/kg was administered into coronary artery by fast bolus (n = 3) or slow infusion (n = 3). Serial ECG-triggered cardiac MRI of T1-weighted segmented turbo fast low-angle shot (FLASH) sequence was conducted and compared with triphenyltetrazolium chloride (TTC) histochemical staining. The contrast ratio and infarct size were quantified and analysed statistically. No cardiovascular side effects were found with local delivery of both agents. After i.c. administration, Gadophrin-2 induced a strong (CR ≥ 1.78) and persistent (≥ 10 h) contrast enhancement of infarcted region. The infarct size defined with Gadophrin-2 was almost identical to that with TTC staining throughout the postcontrast period. With a dose 20 times higher, Gd-DTPA also strongly enhanced infarct-to-normal contrast; however, the enhancement diminished with time, i.e. from early strong to later faint enhancement and eventual loss of contrast. The delineated infarct size was also unstable, i.e. from early overestimation to later underestimation and eventual disappearance of the enhanced infarct. In combination with PTCA procedure, i.c. administration of MRI contrast agents may prove useful for post-procedure verification of diagnosis. The NACA-enhanced MRI may serve as an in vivo surrogate of postmortem histochemical staining for determination of MV. Although applicable in clinical setting, cardiac MRI with nonspecific Gd-DTPA is less reliable and should be performed within less than 1 h after contrast.

KW - Acute myocardial infarction

KW - Intracoronary injection

KW - Metalloporphyrins

KW - MRI

KW - Myocardial viability

KW - Necrosis-avid contrast agents

UR - http://www.scopus.com/inward/record.url?scp=17944383454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17944383454&partnerID=8YFLogxK

U2 - 10.1007/s003300000791

DO - 10.1007/s003300000791

M3 - Article

C2 - 11372627

AN - SCOPUS:17944383454

VL - 11

SP - 876

EP - 883

JO - European Radiology

JF - European Radiology

SN - 0938-7994

IS - 5

ER -